PLX — Protalix BioTherapeutics, Inc.

NYSE · Health Care · Biotechnology · CIK 1006281 ·
Last close
$2.14
Market Cap
$172.42M
52W High
$3.05
52W Low
$1.88
ADV30
793,053
Next earnings
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 33,750,000 29,623,000 21,146,000 18,317,000 102,336,000 41,001,000 35,107,000
Dec 2025 9,122,000 4,503,000 -4,658,000 -5,504,000 82,346,000 14,680,000 34,116,000
Sep 2025 17,851,000 9,527,000 2,131,000 2,355,000 82,264,000 13,647,000 29,356,000
Jun 2025 15,658,000 9,788,000 1,172,000 164,000 78,486,000 17,895,000 28,583,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-11,993,000
Investing CF
$-2,366,000
Financing CF
$9,326,000
CapEx
$-1,638,000
Dividends Paid
Buybacks
EPS Diluted TTM
$0.01
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-384,997,000
Inventory
$25,729,000
Receivables
$8,840,000
ST Investments
$15,593,000
EBIT TTM
$-4,256,000
Pretax Income TTM
$-5,608,000
Interest Exp TTM
$1,352,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$76,381,000
EBITDA
$21,314,000
Free Cash Flow
$6,783,125
Enterprise Value
$126,598,448
Total Cash
$51,083,000
Total Debt
$8,481,000
Shares Out
80,571,642
Trailing EPS
$0.19
Book Value
$0.60
ROE
27.3%
ROA
14.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 52,744,000 -5,500,000 -6,604,000 82,346,000 34,116,000 -11,993,000
Dec 2024 53,399,000 3,917,000 2,932,000 73,417,000 30,206,000 8,674,000
Dec 2023 65,494,000 10,460,000 8,312,000 84,434,000 50,865,000 -1,318,000
Dec 2022 47,638,000 -13,014,000 -14,927,000 55,787,000 66,427,000 -25,000,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.62

Peers — same industry

TickerNameMarket CapLastDaily %
ABOS Acumen Pharmaceuticals, Inc. $174.79M $2.42
TNYA Tenaya Therapeutics, Inc. $169.69M $0.78
IPHA Innate Pharma SA $161.51M $1.72
VXRT Vaxart, Inc. $153.22M $0.63
DTIL PRECISION BIOSCIENCES INC $195.58M $7.58

News headlines (Yahoo Finance, 1h cache)

3 Penny Stocks With Market Caps Larger Than $100M To Consider
2026-05-26 18:05 · Yahoo
PLX: Chiesi Milestone Received
2026-05-14 16:55 · Yahoo
Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary
2026-05-14 00:34 · Yahoo
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...
2026-05-13 23:02 · Yahoo
Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call
2026-05-13 12:19 · Yahoo
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
2026-05-13 10:50 · Yahoo
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
2026-05-06 10:50 · Yahoo
April 2026 Penny Stocks With Promising Potential
2026-04-10 18:05 · Yahoo
Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ...
2026-03-18 19:00 · Yahoo
PLX: 2025 Full Year Results
2026-03-18 17:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.